| Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas (NCT02213913) | University of Chicago | 2014-07-29 |
| Dose Monitoring of Busulfan and Combination Chemotherapy in Hodgkin or Non-Hodgkin Lymphoma Undergoing Stem Cell Transplant (NCT01959477) | Case Comprehensive Cancer Center | 2014-03-01 |
| Genetically Modified T-cell Infusion Following Peripheral Blood Stem Cell Transplant in Treating Patients With Recurrent or High-Risk Non-Hodgkin Lymphoma (NCT01815749) | City of Hope Medical Center | 2013-10-08 |
| Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies (NCT01789255) | National Cancer Institute (NCI) | 2013-06-01 |
| Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas (NCT01805037) | Northwestern University | 2013-03-05 |
| Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies (NCT01529827) | Roswell Park Cancer Institute | 2012-02-28 |
| Bortezomib and Filgrastim to Promote Stem Cell Mobilization in Patients With Non-Hodgkin Lymphoma or Multiple Myeloma (NCT02037256) | Barbara Ann Karmanos Cancer Institute | 2011-07-01 |
| Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies (NCT01273766) | Wake Forest University Health Sciences | 2011-01-01 |
| Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant (NCT01199562) | City of Hope Medical Center | 2010-12-01 |
| Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancers (NCT01254578) | National Cancer Institute (NCI) | 2010-11-24 |
| Vaccine Therapy With or Without Cryosurgery in Treating Patients With Residual, Relapsed, or Refractory B-Cell Non-Hodgkin Lymphoma (NCT01239875) | Mayo Clinic | 2010-11-01 |
| RO4929097 and Capecitabine in Treating Patients With Refractory Solid Tumors (NCT01158274) | National Cancer Institute (NCI) | 2010-06-01 |
| Lenalidomide And Rituximab as Maintenance Therapy in Treating Patients With B-Cell Non-Hodgkin Lymphoma (NCT01045928) | Case Comprehensive Cancer Center | 2010-01-01 |
| Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy (NCT00890747) | National Cancer Institute (NCI) | 2009-08-01 |
| FAU in Treating Patients With Advanced Solid Tumors or Lymphoma (NCT00769288) | National Cancer Institute (NCI) | 2009-07-01 |
| Gossypol, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery (NCT00891072) | National Cancer Institute (NCI) | 2009-07-01 |
| Vorinostat in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma and Liver Dysfunction (NCT00499811) | National Cancer Institute (NCI) | 2007-06-01 |
| Bevacizumab and Cediranib Maleate in Treating Patients With Metastatic or Unresectable Solid Tumor, Lymphoma, Intracranial Glioblastoma, Gliosarcoma or Anaplastic Astrocytoma (NCT00458731) | National Cancer Institute (NCI) | 2007-05-01 |
| PXD101 and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas (NCT00348985) | National Cancer Institute (NCI) | 2006-03-01 |
| SB-715992 in Treating Patients With Metastatic or Unresectable Solid Tumors or Hodgkin's or Non-Hodgkin's Lymphoma (NCT00101244) | National Cancer Institute (NCI) | 2004-11-01 |
| Tanespimycin and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas (NCT00096005) | National Cancer Institute (NCI) | 2004-11-01 |
| MS-275 and Isotretinoin in Treating Patients With Metastatic or Advanced Solid Tumors or Lymphomas (NCT00098891) | National Cancer Institute (NCI) | 2004-10-01 |
| MDX-010 in Treating Patients With Recurrent or Refractory Lymphoma (NCT00089076) | National Cancer Institute (NCI) | 2004-06-01 |
| Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant (NCT00078858) | Fred Hutchinson Cancer Center | 2003-09-01 |
| Bortezomib in Treating Patients With Advanced Cancer and Kidney Dysfunction (NCT00054483) | National Cancer Institute (NCI) | 2003-01-01 |
| Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer (NCT00112593) | Fred Hutchinson Cancer Center | 1999-11-01 |